The purpose of this study was to evaluate the effects of oral supplementation with pomegranate extract on cardiovascular risk, physical function, oxidative stress, and inflammation in hemodialysis (HD) patients. Thirty-three HD subjects were randomized to the pomegranate (POM) or placebo (CON) group. Patients in POM ingested a 1000 mg capsule of a purified pomegranate polyphenol extract 7 days/week for 6 months. Individuals in CON ingested a noncaloric placebo capsule using the same protocol. Measurements were conducted at baseline and repeated 6 months following the start of the intervention. Brachial blood pressure (BP) was obtained using an automatic digital BP monitor. Cardiovascular risk was assessed using ultrasound and arterial tonometry. Blood samples were collected for the measurements of circulating markers of inflammation, oxidative stress, and antioxidant capacity. Muscle strength and physical function were assessed by isokinetic dynamometry, a validated shuttle walk test, and a battery of tests to assess functional fitness. Systolic blood pressure and diastolic blood pressure were reduced by 24±13.7 and 10±5.3 mmHg, respectively, in POM (P<.05). However, the BP differences in POM were no longer significant after controlling for baseline BP. The paraoxonase-1 activity increased by 26.6% (P<.05) in POM, compared to no significant change in CON. However, pomegranate supplementation had no effect on other markers of cardiovascular disease risk, inflammation and oxidative stress, or measures of physical function and muscle strength. While pomegranate extract supplementation may reduce BP and increase the antioxidant activity in HD patients, it does not improve other markers of cardiovascular risk, physical function, or muscle strength.
Get full access to this article
View all access options for this article.
References
1.
U.S. Renal Data System USRDS Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA, 2010.
TonelliM, WiebeN, CulletonB, HouseA, RabbatC, FokM, McAlisterF, GargAX: Chronic kidney disease and mortality risk: A systematic review. J Am Soc Nephrol, 2006; 17:2034–2047.
4.
JohansenKL: Physical functioning and exercise capacity in patients on dialysis. Adv Ren Replace Ther, 1999; 6:141–148.
5.
JohansenKL, ShubertT, DoyleJ, SoherB, SakkasGK, Kent-BraunJA: Muscle atrophy in patients receiving hemodialysis: Effects on muscle strength, muscle quality, and physical function. Kidney Int, 2003; 63:291–297.
6.
DuJ, HuZ, MitchWE: Cellular signals activating muscle proteolysis in chronic kidney disease: A two-stage process. Int J Biochem Cell Biol, 2005; 37:2147–2155.
7.
JohansenKL, ChertowGM, da SilvaM, CareyS, PainterP: Determinants of physical performance in ambulatory patients on hemodialysis. Kidney Int, 2001; 60:1586–1591.
8.
LaneAD, WuPT, KistlerB, FitschenP, TomaykoE, JeongJH, ChungHR, YanH, RanadiveSM, PhillipsS, FernhallB, WilundK: Arterial stiffness and walk time in patients with end-stage renal disease. Kidney Blood Press Res, 2013; 37:142–150.
9.
BergstromJ: Nutrition and mortality in hemodialysis. J Am Soc Nephrol, 1995; 6:1329–1341.
10.
CaglarK, HakimRM, IkizlerTA: Approaches to the reversal of malnutrition, inflammation, and atherosclerosis in end-stage renal disease. Nutr Rev, 2002; 60:378–387.
11.
CachofeiroV, GoicocheaM, de VinuesaSG, OubinaP, LaheraV, LunoJ: Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. Kidney Int, 2008:S4–S9. DOI: 10.1038/ki.2008.516.
12.
HimmelfarbJ: Oxidative stress in hemodialysis. Contrib Nephrol, 2008; 161:132–137.
13.
SarnakMJ, LeveyAS, SchoolwerthAC, CoreshJ, CulletonB, HammLL, McCulloughPA, KasiskeBL, KelepourisE, KlagMJ, ParfreyP, PfefferM, RaijL, SpinosaDJ, WilsonPW: Kidney disease as a risk factor for development of cardiovascular disease: A statement from the american heart association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation, 2003; 108:2154–2169.
14.
BergstromJ, LindholmB, LacsonEJr., OwenWJr., LowrieEG, GlassockRJ, IkizlerTA, WesselsFJ, MoldawerLL, WannerC, ZimmermannJ: What are the causes and consequences of the chronic inflammatory state in chronic dialysis patients?. Semin Dial, 2000; 13:163–175.
15.
BjelakovicG, NikolovaD, GluudLL, SimonettiRG, GluudC: Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev, 2008:CD007176. DOI: 10.1002/14651858.CD007176.
16.
BoazM, SmetanaS, WeinsteinT, MatasZ, GafterU, IainaA, KnechtA, WeissgartenY, BrunnerD, FainaruM, GreenMS: Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (space): Randomised placebo-controlled trial. Lancet, 2000; 356:1213–1218.
17.
TepelM, van der GietM, StatzM, JankowskiJ, ZidekW: The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: A randomized, controlled trial. Circulation, 2003; 107:992–995.
18.
BasuA, PenugondaK: Pomegranate juice: A heart-healthy fruit juice. Nutr Rev, 2009; 67:49–56.
19.
SeeramNP, AviramM, ZhangY, HenningSM, FengL, DreherM, HeberD: Comparison of antioxidant potency of commonly consumed polyphenol-rich beverages in the United States. J Agric Food Chem, 2008; 56:1415–1422.
20.
AviramM, DornfeldL, RosenblatM, VolkovaN, KaplanM, ColemanR, HayekT, PresserD, FuhrmanB: Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to ldl, and platelet aggregation: Studies in humans and in atherosclerotic apolipoprotein e-deficient mice. Am J Clin Nutr, 2000; 71:1062–1076.
21.
KaplanM, HayekT, RazA, ColemanR, DornfeldL, VayaJ, AviramM: Pomegranate juice supplementation to atherosclerotic mice reduces macrophage lipid peroxidation, cellular cholesterol accumulation and development of atherosclerosis. J Nutr, 2001; 131:2082–2089.
22.
AviramM: Review of human studies on oxidative damage and antioxidant protection related to cardiovascular diseases. Free Radic Res, 2000; 33Suppl:S85–S97.
23.
DavidsonMH, MakiKC, DicklinMR, FeinsteinSB, WitchgerM, BellM, McGuireDK, ProvostJC, LikerH, AviramM: Effects of consumption of pomegranate juice on carotid intima-media thickness in men and women at moderate risk for coronary heart disease. Am J Cardiol, 2009; 104:936–942.
24.
AviramM, RosenblatM, GaitiniD, NiteckiS, HoffmanA, DornfeldL, VolkovaN, PresserD, AttiasJ, LikerH, HayekT: Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and ldl oxidation. Clin Nutr, 2004; 23:423–433.
25.
Shema-DidiL, SelaS, OreL, ShapiroG, GeronR, MosheG, KristalB: One year of pomegranate juice intake decreases oxidative stress, inflammation, and incidence of infections in hemodialysis patients: A randomized placebo-controlled trial. Free Radic Biol Med, 2012; 53:297–304.
26.
PanzaJA, EpsteinSE, QuyyumiAA: Circadian variation in vascular tone and its relation to alpha-sympathetic vasoconstrictor activity. N Engl J Med, 1991; 325:986–990.
27.
HiraiT, SasayamaS, KawasakiT, YagiS: Stiffness of systemic arteries in patients with myocardial infarction. A noninvasive method to predict severity of coronary atherosclerosis. Circulation, 1989; 80:78–86.
28.
WilkinsonIB, MacCallumH, FlintL, CockcroftJR, NewbyDE, WebbDJ: The influence of heart rate on augmentation index and central arterial pressure in humans. J Physiol, 2000; 525(Pt 1):263–270.
29.
Van BortelLM, DuprezD, Starmans-KoolMJ, SafarME, GiannattasioC, CockcroftJ, KaiserDR, ThuillezC: Clinical applications of arterial stiffness, task force iii: Recommendations for user procedures. Am J Hypertens, 2002; 15:445–452.
30.
RikliRE: Senior Fitness Test Manual. Human Kinetics, Champaign, IL, 2001.
31.
WinT, JacksonA, GrovesAM, SharplesLD, CharmanSC, LarocheCM: Comparison of shuttle walk with measured peak oxygen consumption in patients with operable lung cancer. Thorax, 2006; 61:57–60.
32.
PriorRL, HoangH, GuL, WuX, BacchioccaM, HowardL, Hampsch-WoodillM, HuangD, OuB, JacobR: Assays for hydrophilic and lipophilic antioxidant capacity (oxygen radical absorbance capacity (orac(fl))) of plasma and other biological and food samples. J Agric Food Chem, 2003; 51:3273–3279.
33.
Witko-SarsatV, FriedlanderM, Capeillere-BlandinC, Nguyen-KhoaT, NguyenAT, ZingraffJ, JungersP, Descamps-LatschaB: Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int, 1996; 49:1304–1313.
34.
GugliucciA, KinugasaE, KotaniK, CaccavelloR, KimuraS: Serum paraoxonase 1 (pon1) lactonase activity is lower in end-stage renal disease patients than in healthy control subjects and increases after hemodialysis. Clin Chem Lab Med, 49:61–67.
35.
HernandezAF, GilF, LenoE, LopezO, RodrigoL, PlaA: Interaction between human serum esterases and environmental metal compounds. Neurotoxicology, 2009; 30:628–635.
36.
RichterRJ, JampsaRL, JarvikGP, CostaLG, FurlongCE: Determination of paraoxonase 1 status and genotypes at specific polymorphic sites. Curr Protoc Toxicol, 2004;Chapter 4:Unit4.12. DOI: 10.1002/0471140856.tx0412s19.
37.
AviramM: Interaction of oxidized low density lipoprotein with macrophages in atherosclerosis, and the antiatherogenicity of antioxidants. Eur J Clin Chem Clin Biochem, 1996; 34:599–608.
38.
RodrigoR, PassalacquaW, ArayaJ, OrellanaM, RiveraG: Implications of oxidative stress and homocysteine in the pathophysiology of essential hypertension. J Cardiovasc Pharmacol, 2003; 42:453–461.
39.
LassegueB, GriendlingKK: Reactive oxygen species in hypertension; an update. Am J Hypertens, 2004; 17:852–860.
40.
RodrigoR, GonzalezJ, PaolettoF: The role of oxidative stress in the pathophysiology of hypertension. Hypertens Res, 2011; 34:431–440.
RodrigoR, BoscoC: Oxidative stress and protective effects of polyphenols: Comparative studies in human and rodent kidney. A review. Comp Biochem Physiol C Toxicol Pharmacol, 2006; 142:317–327.
43.
DuarteJ, AndriambelosonE, DieboltM, AndriantsitohainaR: Wine polyphenols stimulate superoxide anion production to promote calcium signaling and endothelial-dependent vasodilatation. Physiol Res, 2004; 53:595–602.
44.
ZenebeW, PechanovaO, AndriantsitohainaR: Red wine polyphenols induce vasorelaxation by increased nitric oxide bioactivity. Physiol Res, 2003; 52:425–432.
AsgaryS, SahebkarA, AfshaniMR, KeshvariM, HaghjooyjavanmardS, Rafieian-KopaeiM: Clinical evaluation of blood pressure lowering, endothelial function improving, hypolipidemic and anti-inflammatory effects of pomegranate juice in hypertensive subjects. Phytother Res, 2014; 28:193–199.
47.
AviramM, DornfeldL: Pomegranate juice consumption inhibits serum angiotensin converting enzyme activity and reduces systolic blood pressure. Atherosclerosis, 2001; 158:195–198.
48.
PoredosP: Intima-media thickness: Indicator of cardiovascular risk and measure of the extent of atherosclerosis. Vasc Med, 2004; 9:46–54.
49.
BenedettoFA, MallamaciF, TripepiG, ZoccaliC: Prognostic value of ultrasonographic measurement of carotid intima media thickness in dialysis patients. J Am Soc Nephrol, 2001; 12:2458–2464.
50.
HauerK, HildebrandtW, SehlY, EdlerL, OsterP, DrogeW: Improvement in muscular performance and decrease in tumor necrosis factor level in old age after antioxidant treatment. J Mol Med (Berl), 2003; 81:118–125.
51.
TromboldJR, BarnesJN, CritchleyL, CoyleEF: Ellagitannin consumption improves strength recovery 2–3 days after eccentric exercise. Med Sci Sports Exerc, 2010; 42:493–498.
52.
TromboldJR, ReinfeldAS, CaslerJR, CoyleEF: The effect of pomegranate juice supplementation on strength and soreness after eccentric exercise. J Strength Cond Res, 2011; 25:1782–1788.
53.
HimmelfarbJ, IkizlerTA, EllisC, WuP, ShintaniA, DalalS, KaplanM, ChoncholM, HakimRM: Provision of antioxidant therapy in hemodialysis (path): A randomized clinical trial. J Am Soc Nephrol, 2014; 25:623–633.
54.
RockW, RosenblatM, Miller-LotanR, LevyAP, EliasM, AviramM: Consumption of wonderful variety pomegranate juice and extract by diabetic patients increases paraoxonase 1 association with high-density lipoprotein and stimulates its catalytic activities. J Agric Food Chem, 2008; 56:8704–8713.
55.
RosenblatM, VolkovaN, AttiasJ, MahamidR, AviramM: Consumption of polyphenolic-rich beverages (mostly pomegranate and black currant juices) by healthy subjects for a short term increased serum antioxidant status, and the serum's ability to attenuate macrophage cholesterol accumulation. Food Funct, 2010; 1:99–109.
56.
TavoriH, KhatibS, AviramM, VayaJ: Characterization of the pon1 active site using modeling simulation, in relation to pon1 lactonase activity. Bioorg Med Chem, 2008; 16:7504–7509.
57.
TavoriH, VayaJ, AviramM: Paraoxonase 1 attenuates human plaque atherogenicity: Relevance to the enzyme lactonase activity. Adv Exp Med Biol, 2010; 660:99–111.
SeeramNP, HenningSM, ZhangY, SuchardM, LiZ, HeberD: Pomegranate juice ellagitannin metabolites are present in human plasma and some persist in urine for up to 48 hours. J Nutr, 2006; 136:2481–2485.
60.
SeeramNP, ZhangY, McKeeverR, HenningSM, LeeRP, SuchardMA, LiZ, ChenS, ThamesG, ZerlinA, NguyenM, WangD, DreherM, HeberD: Pomegranate juice and extracts provide similar levels of plasma and urinary ellagitannin metabolites in human subjects. J Med Food, 2008; 11:390–394.
61.
RosenblatM, HayekT, AviramM: Anti-oxidative effects of pomegranate juice (pj) consumption by diabetic patients on serum and on macrophages. Atherosclerosis, 2006; 187:363–371.
